Strona 10 - Najlepsi lekarze w Izraelu — proszę uzyskać konsultację online

Dr. Boaz Liberman, MD, is an orthopedic oncologist and sarcoma surgeon for adults and children. He directs the Orthopedic Oncology Unit and serves as Vice Head of Orthopedic Surgery at Sheba Medical Center. His focus is limb-sparing cancer surgery with functional reconstruction. He performs complex joint reconstruction, revision arthroplasty, MRgFUS, and reconstruction after bone metastases.

Education and training: MD, Tel Aviv University. Orthopedic surgery residency, Sheba Medical Center. Fellowships in Adult Reconstruction at Mount Sinai Hospital, Toronto, and in Orthopedic Oncology at Mount Sinai Hospital and Princess Margaret Cancer Centre. He is board-certified in Orthopedic Surgery and in Orthopedic Oncology Surgery. He is a Clinical Instructor at Tel Aviv University. Memberships include the Israel Medical Association, Israel Orthopedic Association, AATB, and EATB. He also serves on national advisory committees. His research covers bone and soft tissue sarcomas, serum markers, imaging-guided therapies, MRI arthrography, and the biomechanics of bone treated with MRgFUS.

Dr. Ram (Rami) Palti is an orthopedic hand and upper limb surgeon. He has over 20 years of experience at the Hand Surgery Unit of Sheba Medical Center. He focuses on reconstructive surgery for congenital hand anomalies and deformity correction. He also performs complex microsurgery, nerve repair, and tendon reconstruction.

He earned his MD from Tel Aviv University. He completed an orthopedic residency at Sheba Medical Center. He completed fellowships in Upper Extremity Surgery at NYU Hospital for Joint Diseases and in Hand, Elbow and Peripheral Nerve Surgery at Royal North Shore Hospital. He also received advanced training in congenital upper limb surgery at Westmead Children’s Hospital.

He is a certified medical expert for the Israeli National Insurance Institute. He consults for the Israeli Ministry of Defense Rehabilitation Department and advises legal and government bodies. His practice emphasizes precise microsurgery with functional rehabilitation.

Dr. Pazit Beckerman is a nephrologist with over 24 years of clinical practice in Israel. She specializes in chronic kidney disease (CKD), acute kidney injury (AKI), hemodialysis and peritoneal dialysis, hypertension-related kidney disease, glomerular diseases and proteinuria, electrolyte disorders, and kidney involvement in systemic diseases.

She served as Acting Director in 2020, Deputy Director from 2018 to 2020, and Senior Physician in the Department of Nephrology at Sheba Medical Center. She also heads the Israeli Dialysis Registry.

Education and training: MD, Hebrew University–Hadassah. Nephrology residency, Hadassah. Fellowship in nephrology, Sheba Medical Center. Biomedical Computational Studies, Bar-Ilan University. Postdoctoral fellowship, University of Pennsylvania.

Her research focuses on AKI, immune-related kidney complications, and chronic kidney disease. She has authored many publications. She is a member of the American Society of Nephrology and a board member of the Israeli Society of Nephrology and Hypertension.

Lekarz specjalizuje się w wydłużaniu kończyn i operacjach rekonstrukcyjnych z wykorzystaniem metody Ilizarowa, koncentrując się na korekcji deformacji kończyn i leczeniu stanów pourazowych. Ekspertyza obejmuje chirurgiczne i niechirurgiczne leczenie złamań, leczenie artretyzmu z zachowaniem stawów oraz opiekę ortopedyczną dla dzieci z porażeniem mózgowym. Lekarz ukończył Uniwersytet Hebrajski w Jerozolimie i ukończył specjalizację z ortopedii w Centrum Medycznym Hadassah, z dalszym szkoleniem w Szpitalu Specjalnej Chirurgii w Nowym Jorku. Aktywnie uczestniczy w edukacji medycznej i badaniach, jest członkiem znanych towarzystw ortopedycznych.<\/p>

Lekarz ukończył Wydział Medyczny Uniwersytetu Hebrajskiego w 1987 roku i specjalizuje się w chirurgii i chirurgii kolorektalnej. Związany z Centrum Medycznym Hadassah, lekarz jest instruktorem chirurgii od 1995 roku, wykładowcą od 1999 roku i starszym wykładowcą od 2005 roku. Lekarz kieruje programem dla studentów medycyny w Departamencie Chirurgii od 1997 roku i jest dyrektorem programu rezydentury w Departamencie Chirurgii od 2000 roku. Certyfikowany w chirurgii ogólnej w Izraelu od 1998 roku, lekarz jest również członkiem różnych stowarzyszeń chirurgicznych.<\/p>

Lekarz jest wysoko wykwalifikowanym specjalistą w dziedzinie onkologii dziecięcej i hematoonkologii w Centrum Medycznym Hadassah, uznanym na liście najlepszych lekarzy w Izraelu według Forbes na lata 2019-2020. Z ponad dwudziestoletnim doświadczeniem w specjalizacji w pediatrii, hematoonkologii dziecięcej i haploidentycznym przeszczepie szpiku kostnego, lekarz jest wybitną postacią w tej dziedzinie.<\/p>

Lekarz jest absolwentem Uniwersytetu w Tel Awiwie i aktywnie uczestniczy w stowarzyszeniach zawodowych, w tym w Izraelskim Towarzystwie Hematologii i Onkologii Dziecięcej, Izraelskim Stowarzyszeniu Walki z Rakiem, Międzynarodowym Stowarzyszeniu Onkologii oraz Międzynarodowym Towarzystwie Onkologii Dziecięcej. Główne obszary zainteresowań obejmują siatkówczaka, medycynę precyzyjną i onkologię dziecięcą.<\/p>

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.

Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.

He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.

Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.

Dr. Anton Wohl leads the Brain Tumors Unit at Sheba Medical Center (since 2026). He is a neurosurgeon specializing in neuro-oncology, brain tumor surgery, and stereotactic radiosurgery.

He performs complex tumor operations with intraoperative MRI and functional mapping. He also uses fluorescence guidance, neuronavigation, and awake craniotomy to help remove tumors safely and preserve function.

Accreditations: Israeli Board Certification in Neurosurgery; Israeli medical license; advanced international fellowships and training, including the Mayo Clinic (USA).

Research: author and co-author of peer-reviewed publications on glioblastoma, malignant brain tumors, radiosurgery, and experimental therapies.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Dr. David (Dudi) Mishali, MD, is Director of Pediatric and Congenital Cardiothoracic Surgery at Sheba Medical Center. He treats infants and children with congenital heart defects. His work includes rare, high-risk anomalies and complex newborn reconstructions.

He trained internationally. He completed his residency at Rabin Medical Center and clinical fellowships in cardiac surgery at the Cleveland Clinic and in congenital pediatric cardiothoracic surgery at UCSF. He is board certified in cardiothoracic surgery. He developed and implemented minimally invasive methods that reduce surgical trauma and improve cosmetic results.

He is a Senior Lecturer at Tel Aviv University’s Sackler Faculty of Medicine. He has written many peer-reviewed papers and book chapters, including on point-of-care testing in children during cardiopulmonary bypass and on accessory mitral valve tissue. He holds a leadership role at a hospital ranked among the world’s top 10.

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.

He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.

Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.

Prof. Roy Mashiach, MD, is the Director of Gynecology at Sheba Medical Center. He is a leading expert in minimally invasive gynecologic surgery with over 30 years of experience. He focuses on laparoscopic and hysteroscopic hysterectomy. He also performs myoma removal, treats endometriosis, and offers fertility‑preserving procedures.

Recognition and roles: Named to Forbes Israel’s Best Doctors. Recipient of the Daniel F. Kott Award (AAGL). Chairman of the Israeli Society of Gynecological Endoscopy. Director of the Gynecologic Simulation Unit (M.S.R.). Clinical Associate Professor at Tel Aviv University. Training: MD from Tel Aviv University. Specialization at Lis Maternity & Women’s Hospital. Fellowship in Advanced Endoscopy at Université d’Auvergne.

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

RESEARCH ACTIVITY

1998–2000 — Conducted research on the genesis of cancer at The Royal Marsden Hospital (England).

PUBLICATIONS

Authored numerous peer-reviewed articles in scientific journals. Selected topics include:

Oncotype Dx Recurrence Score in BRCA1/2 germline mutation carriers with hormone receptor-positive breast cancer.

TP53 missense mutation recurrence in cancer patients of Arab descent.

Adjuvant autologous vaccine for stage III microscopic melanoma: biomarker survival and enhanced response to CTLA-4 blockade.

Prognostic significance of (R)CA15-3 assay in primary breast cancer.

Diagnostic and prognostic value of comparative thymidine kinase 1 (TK1) activity assays in breast cancer patient serum.

Complete remission in a BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma treated with cisplatin.

Autologous vaccine-induced antitumor and self-reactive immune responses in melanoma: impact on patient survival and dependence on MHC class II expression.

PROFESSIONAL AFFILIATIONS

Israeli Society of Clinical Oncology

Israel Medical Association

AWARDS & GRANTS

Cancer Genetics Research Foundation Award

Landau Prize

Judith Segal Memorial Award

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.